Drug Profile
Rivastigmine transdermal patch - Luye Pharma
Alternative Names: Kingsmin; LY 03013; LY 30410; RID-TDS; Rivastigmine MD; Rivastigmine transdermal - Luye Pharma; RivirecLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Acino
- Developer Luye Pharma Group
- Class Antidementias; Phenylcarbamates; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alzheimer's disease
Most Recent Events
- 05 Feb 2024 Luye Pharma grants commercialization rights of rivastigmine transdermal patches to Myung In in South Korea
- 05 Feb 2024 Luye Pharma intends to launch rivastigmine transdermal multi day in South Korea, Japan, Mexico, Thailand and European countries
- 31 Oct 2023 National Medical Products Administration (NMPA) approves Marketing Authorization Aapplication for rivastigmine twice weekly transdermal patch in Alzheimer's disease